Recon: Lilly’s weekly insulin found comparable to daily products; Biogen, Ionis end ALS drug program after early-stage miss

• Lilly’s weekly insulin works as well as daily products, new studies show (STAT)
• Treating chronic pain requires much more than medications (STAT)
• US unveils proposal to ease restrictions on marijuana (Reuters)
• US FDA approves Amgen drug for small cell lung cancer (Reuters)
• As childhood asthma worsens, insurers restrict access to an essential medication (STAT)
• Biogen CEO Viehbacher undaunted by Lilly's impending Alzheimer's therapy, saying it will ‘expand’ market (Endpoints)
• J&J makes small I&I acquisition to enter competitive IL-13, TSLP arena (Endpoints)
• House panel advances bills targeting rare disease, priority review vouchers (Endpoints)
• US Appeals Court Backs Dismissal Of Bystolic ‘Pay-For-Delay’ Case (Pink Sheet)

• WuXi Biologics pauses Massachusetts build; Novo Holdings nabs majority stake in pharma tools firm (Endpoints)
• Novo Nordisk is optimistic that Kalundborg fire won't delay expansion (Reuters)
• GSK, UK government budget £130M to fight global antimicrobial resistance (Endpoints)
• As Biosecure Bill Mores Forward, Clock Ticking For Industry To Move Away From Chinese CDMOs (Pink Sheet)
• Drug Shortages: Pharma Decries 'Yet Another Tax' For Companies In Belgium (Pink Sheet)
• EU Coordination Key To Speeding Up Combined Studies Of Drugs & IVDs/Devices (Pink Sheet)

• PDS Biotech’s survival benefit is absurdly overstated (STAT)
• Biogen and Ionis abandon ALS drug after disappointing early-stage trial (Endpoints)
• Biogen, Ionis drop ALS treatment after study failure (STAT)
• AstraZeneca's successor to Covid blockbuster Evusheld succeeds in Phase 3 trial (Endpoints)
• Blackstone wants in on red-hot immunology market (STAT)
• Obesity drug from Roche succeeds in early test, sending company shares up (STAT)
• Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S. (STAT)
• Novo to test Wegovy and other obesity drugs against alcohol-related liver disease (STAT)
• Element Biosciences, an Illumina rival, on its genomics ambitions — and why it hasn’t gone public (STAT)
• Roche teases 'encouraging' Phase 1 data for weight loss drug from $2.7B Carmot buyout (Endpoints)
• Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update (Endpoints)
• Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand Pharma (Endpoints)
• Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount (Endpoints)
• BeiGene looks at new partnerships, with a full cancer pipeline and growing footprint (Endpoints)

• Cue Health’s Covid-19 tests could give false results, FDA warns (STAT)
• Stereotaxis inks APT buyout to gain catheters for surgical robots (MedTech Dive)
• Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage (MedTech Dive)
• Getinge to limit US sales of heart devices after FDA safety warning (MedTech Dive)
• GE Healthcare warns of cybersecurity risks in ultrasound devices, software (MedTech Dive)

• My rendezvous with the raw milk black market: quick, easy, and unchecked by the FDA (STAT)
• CVS is willing to dump 10% of its Medicare Advantage members next year (STAT)
• Boston Scientific recalls more than 1M angiographic catheters (MedTech Dive)
• Abbott recalls Heartmate pump after 70 injuries, 2 deaths reported (MedTech Dive)